Ticagrelor API manufacturers

compare suppliers & send inquiries for free

Looking for Ticagrelor 274693-27-5?

Description:

Here you will find a list of producers, manufacturers and traders of Ticagrelor. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Ticagrelor 

Synonyms:

Brilinta  

Cas Number:

274693-27-5 

DrugBank number:

DB08816 

Unique Ingredient Identifier:

GLH0314RVC

Ticagrelor is a type of Platelet Aggregation Inhibitors

Platelet Aggregation Inhibitors are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the field of cardiology and thrombosis management. These inhibitors play a vital role in preventing platelet aggregation, a process responsible for the formation of blood clots. By inhibiting platelet aggregation, these APIs reduce the risk of arterial thrombosis, which can lead to severe cardiovascular events like heart attacks and strokes.

Platelet Aggregation Inhibitors primarily work by targeting specific receptors on platelet cells, thereby impeding their activation and subsequent aggregation. The most commonly utilized APIs in this category include acetylsalicylic acid (aspirin), clopidogrel, ticagrelor, and prasugrel. These drugs are available in various forms, such as tablets, capsules, and intravenous formulations, allowing flexibility in their administration.

The effectiveness of Platelet Aggregation Inhibitors lies in their ability to prevent platelets from adhering to each other and forming clots within blood vessels. This property is especially crucial in patients with a high risk of cardiovascular events, such as those with a history of heart disease, diabetes, or peripheral artery disease.

While Platelet Aggregation Inhibitors are generally safe and effective, they can also carry potential side effects, including bleeding complications. Therefore, their administration requires careful consideration of individual patient characteristics and risk factors.

In conclusion, Platelet Aggregation Inhibitors represent a significant category of pharmaceutical APIs used for the prevention of platelet aggregation and subsequent blood clot formation. By inhibiting this process, they contribute to the management and reduction of cardiovascular events, offering critical benefits to patients at risk.

• Apino Pharma Co., Ltd. from China
• Acura Labs from India
• Solfyn International LLP from India
• SENOVA Technology Co., Ltd. from China
• Zhejiang Hisun Pharma from China
• Changzhou Pharma from China
• Wuhan ZhongYou  from China
• Kaiyuan Hengtai Pharma Co Ltd from China
• Sichuan Benepure from China
• Raks Pharma from India
• Megafine Pharma (P) Ltd. from India
• HEC Pharm from Germany
• Astrazeneca from Sweden
• Honour Lab from India
• Teva API from Israel
• Glenmark Pharma from India
• Shaoxing Hantai Pharma from China
• MSN Organics from India
• Mylan from India
• Jubilant Generics from India
• Jiangxi Synergy from China
• Dr. Reddy's from India
• Micro Labs from India
• Alembic Pharma from India
• Lek Pharma from Slovenia

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.